+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Monoclonal Antibodies Market Size, Share & Trends Analysis Report by Source Type (Chimeric, Murine, Humanized, Human), by Production Type (In Vivo, In Vitro), by Application, by End-use, by Region, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 120 Pages
  • August 2022
  • Region: Global
  • Grand View Research
  • ID: 5653994
Description Jump to:

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.30% in the forecast period. Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive market growth in the forecast period. 

The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth. 

In addition, several government entities are fueling clinical research activities and expanding the scope of applications for mAb therapies. For instance, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for the reduction of asthma attacks and the improvement of lung functionality in children. Similarly, in March 2021, the U.S. Department of Health and Human Services invested USD 150 million in increasing patient access to monoclonal antibody therapeutics for COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen growth prospects. 

Furthermore, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. Demand for such recombinant antibodies is driven by increasing commercial prospects and quality requirements that may not be fulfilled by hybridoma technologies. Hence, with the increasing commercial viability of recombinant technologies, the market is expected to witness significant growth. 

The COVID-19 pandemic has created several market expansion opportunities by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for mitigation of the disease due to their safety and effectiveness, several mAbs such as Eli Lilly’s bebtelovimab, and GlaxoSmithKline & Vir Biotechnology’s sotrovimab have attained emergency use authorizations from the U.S. FDA. Such authorizations are likely to broaden the horizons for the growth of mAbs applications and propel market growth.

Monoclonal Antibodies Market Report Highlights

  • By source type, the human mAbs segment held the largest share of 54.07% in 2021 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies
  • In vitro production type held a dominating share of 78.45% in 2021 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities
  • The oncology segment dominated the market in 2021 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies
  • Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics
  • North America accounted for 46.2% of the market value in 2021 due to the availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others
  • The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Source Types
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using a bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Source types
1.10 List of Primary Source types
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List Of Abbreviations

Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Market Summary

Chapter 3 Monoclonal Antibodies Market Variables, Trends & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation & Scope
3.3 Market Driver Analysis
3.3.1 Increasing Incidences Of Chronic Diseases
3.3.2 Technological Advancements
3.3.3 Growing Awareness Levels
3.4 Market Restraint Analysis
3.4.1 High Cost Of Therapeutic Mabs
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
3.7 COVID-19 Impact Analysis
3.8 Penetration & Growth Prospect Mapping

Chapter 4 Monoclonal Antibodies Market - Segment Analysis, by Source Type, 2018 - 2030 (USD Billion)
4.1 Monoclonal Antibodies Market: Source Type Movement Analysis
4.2 Murine
4.2.1 Murine Market Estimates And Forecast, 2018 - 2030 (USD Billion)
4.3 Chimeric
4.3.1 Chimeric Market Estimates And Forecast, 2018 - 2030 (USD Billion)
4.4 Humanized
4.4.1 Humanized Market Estimates And Forecast, 2018 - 2030 (USD Billion)
4.5 Human
4.5.1 Human Market Estimates And Forecast, 2018 - 2030 (USD Billion)

Chapter 5 Monoclonal Antibodies Market - Segment Analysis, By Production Type, 2018 - 2030 (USD Billion)
5.1 Monoclonal Antibodies Market: Production Type Movement Analysis
5.2 In Vivo
5.2.1 In Vivo Market Estimates And Forecast, 2018 - 2030 (USD Billion)
5.3 In Vitro
5.3.1 In Vitro Market Estimates And Forecast, 2018 - 2030 (USD Billion)

Chapter 6 Monoclonal Antibodies Market - Segment Analysis, By Application, 2018 - 2030 (USD Billion)
6.1 Monoclonal Antibodies Market: Application Movement Analysis
6.2 Oncology
6.2.1 Oncology Market Estimates And Forecast, 2018 - 2030 (USD Billion)
6.3 Autoimmune Diseases
6.3.1 Autoimmune Diseases Market Estimates And Forecast, 2018 - 2030 (USD Billion)
6.4 Infectious Diseases
6.4.1 Infectious Diseases Market Estimates And Forecast, 2018 - 2030 (USD Billion)
6.5 Neurological Diseases
6.5.1 Neurological Diseases Market Estimates And Forecast, 2018 - 2030 (USD Billion)
6.6 Others
6.6.1 Other Applications Market Estimates And Forecast, 2018 - 2030 (USD Billion)

Chapter 7 Monoclonal Antibodies Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Billion)
7.1 Monoclonal Antibodies Market: End-Use Movement Analysis
7.2 Hospitals
7.2.1 Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Billion)
7.3 Specialty Centers
7.3.1 Specialty Centers Market Estimates And Forecast, 2018 - 2030 (USD Billion)
7.4 Others
7.4.1 Other End-Use Market Estimates And Forecast, 2018 - 2030 (USD Billion)

Chapter 8 Monoclonal Antibodies Market - Segment Analysis, By Region, 2018 - 2030 (USD Billion)
8.1 Monoclonal Antibodies Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.2.2 U.S.
8.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3.2 Uk
8.3.2.1 Uk Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3.3 Germany
8.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3.4 France
8.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3.5 Italy
8.3.5.1 Italy Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.3.6 Spain
8.3.6.1 Spain Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4 Asia Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4.4 India
8.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4.5 Australia
8.4.5.1 Australia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.4.6 South Korea
8.4.6.1 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.5 Latin America
8.5.1 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.5.3 Mexico
8.5.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Billion)
8.6 Middle East and Africa
8.6.1 Middle-East And Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Billion)
8.6.4 Uae
8.6.4.1 Uae Market Estimates And Forecast, 2018 - 2030 (USD Billion)

Chapter 9 Competitive Analysis
9.1 Strategy Framework
9.2 Company/Competition Categorization
9.3 Company Profiles
9.3.1 NOVARTIS AG
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 PFIZER INC
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 AMGEN INC.
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 GlaxoSmithKline plc
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.3.4 Strategic Initiatives
9.3.5 MERCK & CO., INC.
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 DAIICHI SANKYO COMPANY, LIMITED
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 ABBOTT LABORATORIES
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 ASTRAZENECA PLC
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 ELI LILLY AND COMPANY
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 JOHNSON & JOHNSON SERVICES, INC.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 BAYER AG
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 BRISTOL MYERS SQUIBB
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives
9.3.13 F. HOFFMAN-LA ROCHE LTD.
9.3.13.1 Company Overview
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 VIATRIS INC.
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 BIOGEN INC.
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 THERMO FISHER SCIENTIFIC, INC.
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 NOVO NORDISK A/S
9.3.17.1 Company Overview
9.3.17.2 Financial Performance
9.3.17.3 Product Benchmarking
9.3.17.4 Strategic Initiatives
9.3.18 SANOFI S.A.
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 MERCK KGAA
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives

List of Tables
Table 1 Global monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
Table 2 Global monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 3 Global monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 4 Global monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 5 Global monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 6 North America monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 7 North America monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 8 North America monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 9 North America monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 10 U.S. monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 11 U.S. monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 12 U.S. monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 13 U.S. monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 14 Canada monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 15 Canada monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 16 Canada monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 17 Canada monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 18 Europe monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 19 Europe monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 20 Europe monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 21 Europe monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 22 UK monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 23 UK monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 24 UK monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 25 UK monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 26 Germany monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 27 Germany monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 28 Germany monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 29 Germany monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 30 France monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 31 France monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 32 France monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 33 France monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 34 Italy monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 35 Italy monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 36 Italy monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 37 Italy monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 38 Spain monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 39 Spain monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 40 Spain monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 41 Spain monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 42 Asia Pacific monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 43 Asia Pacific monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 44 Asia Pacific monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 45 Asia Pacific monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 46 Japan monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 47 Japan monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 48 Japan monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 49 Japan monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 50 China monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 51 China monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 52 China monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 53 China monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 54 India monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 55 India monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 56 India monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 57 India monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 58 Australia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 59 Australia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 60 Australia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 61 Australia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 62 South Korea monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 63 South Korea monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 64 South Korea monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 65 South Korea monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 66 Latin America monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 67 Latin America monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 68 Latin America monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 69 Latin America monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 70 Brazil monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 71 Brazil monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 72 Brazil monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 73 Brazil monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 74 Mexico monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 75 Mexico monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 76 Mexico monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 77 Mexico monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 78 Middle East & Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 79 Middle East & Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 80 Middle East & Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 81 Middle East & Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 82 South Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 83 South Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 84 South Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 85 South Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 86 Saudi Arabia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 87 Saudi Arabia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 88 Saudi Arabia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 89 Saudi Arabia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 90 UAE monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 91 UAE monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 92 UAE monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 93 UAE monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Monoclonal antibodies market segmentation
Figure 8 Market driver relevance analysis (current & future impact)
Figure 9 Market restraint relevance analysis (current & future impact)
Figure 10 Penetration & growth prospect mapping
Figure 11 SWOT analysis, by factor (political & legal, economic and technological)
Figure 12 Porter’s five forces analysis
Figure 13 Market penetration vs growth prospect mapping
Figure 14 Monoclonal antibodies market: Source type outlook and key takeaways
Figure 15 Monoclonal antibodies market: Source type movement analysis
Figure 16 Murine market, 2018 - 2030 (USD Billion)
Figure 17 Chimeric market, 2018 - 2030 (USD Billion)
Figure 18 Humanized market, 2018 - 2030 (USD Billion)
Figure 19 Human market, 2018 - 2030 (USD Billion)
Figure 20 Monoclonal antibodies market: Production type outlook and key takeaways
Figure 21 Monoclonal antibodies market: Production type movement analysis
Figure 22 In vivo market, 2018 - 2030 (USD Billion)
Figure 23 In vitro market, 2018 - 2030 (USD Billion)
Figure 24 Monoclonal antibodies market: Application outlook and key takeaways
Figure 25 Monoclonal antibodies market: Application movement analysis
Figure 26 Oncology market, 2018 - 2030 (USD Billion)
Figure 27 Autoimmune diseases market, 2018 - 2030 (USD Billion)
Figure 28 Infectious diseases market, 2018 - 2030 (USD Billion)
Figure 29 Neurological diseases market, 2018 - 2030 (USD Billion)
Figure 30 Other applications, 2018 - 2030 (USD Billion)
Figure 31 Monoclonal antibodies market: End-use outlook and key takeaways
Figure 32 Monoclonal antibodies market: End-use movement analysis
Figure 33 Hospitals market, 2018 - 2030 (USD Billion)
Figure 34 Specialty centres, 2018 - 2030 (USD Billion)
Figure 35 Other end-use market, 2018 - 2030 (USD Billion)
Figure 36 Regional market: Key takeaways
Figure 37 Regional outlook, 2018 & 2030
Figure 38 North America monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 39 U.S. monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 40 Canada monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 41 Europe monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 42 UK monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 43 Germany monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 44 France monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 45 Italy monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 46 Spain monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 47 Asia Pacific monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 48 Japan monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 49 China monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 50 India monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 51 Australia monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 52 South Korea monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 53 Latin America monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 54 Brazil monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 55 Mexico monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 56 MEA monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 57 South Africa monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 58 Saudi Arabia monoclonal antibodies market, 2018 - 2030 (USD Billion)
Figure 59 UAE monoclonal antibodies market, 2018 - 2030 (USD Billion)

Companies Mentioned

  • Abbott Laboratories
  • Amgen Inc.
  • Astrazeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi S.A.
  • Thermo Fisher Scientific, Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedAugust 2022
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 210.06 Billion
Forecasted Market Value ( USD ) by 2030 $ 494.53 Billion
Compound Annual Growth Rate11.3%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030 - Product Image

Monoclonal Antibodies Market by Source Type, Production Type, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Drug Class, Application - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Monoclonal Antibodies (MAs) Global Market Report 2024 - Product Image

Monoclonal Antibodies (MAs) Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Breast Cancer Monoclonal Antibodies Global Market Report 2024 - Product Image

Breast Cancer Monoclonal Antibodies Global Market Report 2024

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.